Charles River partnership goes beyond traditional FFS model, says Nimbus

By Melissa Fassbender contact

- Last updated on GMT

The partnership aims to advance programs in immunology, metabolic disorders, and oncology. (Image: iStock/Pinkypills)
The partnership aims to advance programs in immunology, metabolic disorders, and oncology. (Image: iStock/Pinkypills)

Related tags: Charles river, Clinical trial

Charles River Laboratories and Nimbus Therapeutics have entered a multi-year strategic partnership to advance programs from early hit identification through Investigational New Drug (IND) submission.

The new programs will cover various disease areas, including immunology, metabolic disorders, and oncology.

Per the agreement, Charles River is eligible to receive milestone payments from Nimbus for undisclosed program advancements.

While the companies have previously worked together on a project-by-project basis, the establishment of the official partnership “signals the next phase in [the] relationship​,” Birgit Girshick, Corporate Senior Vice President, Global Discovery Services at Charles River Labs told Outsourcing-Pharma.com.

Nimbus and Charles River will work together closely throughout their full drug discovery program​,” she said. “We’re excited to work with Nimbus to help them push their programs through the drug discovery pipeline and to provide the scalability they require to advance an increased number of programs​.”

Jeb Keiper, Chief Financial Officer and Chief Business Officer at Nimbus Therapeutics, explained that the Cambridge, Massachusetts-based biotechnology company has never had its own labs, and instead, has a history of collaborative, fee-for-service (FFS) relationships with CROs. 

This partnership goes much beyond the traditional FFS model but is a true project-based risk sharing, where CRL performs service at risk, and can earn milestones for successful program advancement​,” Keiper told us.

Scientific staff at Nimbus and Charles River will jointly manage the project, though Charles River will execute the trial.

We see our partnership as one focused on streamlining the drug discovery process—instead of partnering with as many as 25 CROs at different stages, Nimbus will work with Charles River from early hit identification through IND submission​,” said Girshick. “Our goal is to work side-by-side with their researchers and become engrained, making our combined team stronger and more effective​.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars